|
Market Closed -
Nasdaq
16:00:00 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 138.36 USD | +0.16% |
|
+3.87% | +12.73% |
| 08-11 | Global drugmakers invest billions to boost US presence | RE |
| 08-11 | Nucleai And Gilead Sciences Advance AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 172B | - | ||||
| 1,052B | |||||
| 627B | - | - | - | ||
| 441B | |||||
| 349B | |||||
| 287B |
- Stock Market
- Stocks
- GILD Stock
- Charts Gilead Sciences, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
